Effect of propranolol, bisoprolol and terbutaline in acute brain injury induced by malathion in the rat Article Swipe
Omar ME Abdel-Salam
,
Fatma A. Morsy
,
Amany A. Sleem
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.54905/disssi.v17i39.e9dd1010
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.54905/disssi.v17i39.e9dd1010
The pharmacological management of acute malathion poisoning entails besides the use of the specific antidotes atropine and oximes, the administration of other drugs for controlling associated cardiac and respiratory problems.In this study, we aimed to investigate the effect of the non-selective β-adrenoceptor blocker propranolol, the selective β1-adrenoceptor antagonist bisoprolol as well as the bronchodilator drug and the selective β2-adrenoceptor agonist terbutaline, either alone or in combination with atropine on brain oxidative stress and neuronal damage caused by acute malathion administration.Rats were treated with malathion at 150 mg/kg by intraperitoneal (i.p.) injection for two days either alone or combined with propranolol, bisoprolol or turbutaline all at the dose of 1 mg/kg, i.p.Brain damage was assessed by measuring the levels of the oxidative stress biomarkers malondialdehyde, reduced glutathione and nitric oxide in brain tissue and by brain histopathology.Results indicated significant increase in the brain lipid peroxidation marker malondialdehyde and nitric oxide as well as depletion of reduced glutathione in brain of malathion only-treated rats.In the cerebral cortex, focal homogenous deeply eosinophilic plaques, gliosis, neuronal apoptosis, necrosis, perineuronal vacuolation and spongiform degeneration were observed after exposure to malathion.The biochemical changes of malathion were decreased by atropine and β-blockers in addition to marked amelioration of the malathion-induced histopthaological effects.The administration of terbutaline to malathion-treated rats had no significant effects on brain oxidative stress.The extent of histological brain damage (neurodegeneration) was not reduced after terbutaline.The administration of atropine was able to ameliorate the neuropathological changes in brain of rats treated with malathion and βadrenergic antagonists but not in case of terbutaline.Collectively, the present results indicate that β-blockade may decrease the neurodegeneration in brain of malathion-treated rats.The results also suggest a role for β-adrenoceptor stimulation in the development of the cerebral damage by malathion.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.54905/disssi.v17i39.e9dd1010
- https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdf
- OA Status
- hybrid
- References
- 36
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4387531653
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4387531653Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.54905/disssi.v17i39.e9dd1010Digital Object Identifier
- Title
-
Effect of propranolol, bisoprolol and terbutaline in acute brain injury induced by malathion in the ratWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-06-15Full publication date if available
- Authors
-
Omar ME Abdel-Salam, Fatma A. Morsy, Amany A. SleemList of authors in order
- Landing page
-
https://doi.org/10.54905/disssi.v17i39.e9dd1010Publisher landing page
- PDF URL
-
https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdfDirect OA link when available
- Concepts
-
Terbutaline, Propranolol, Bisoprolol, Malathion, Anesthesia, Medicine, Pharmacology, Internal medicine, Biology, Asthma, Agronomy, Heart failure, PesticideTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
36Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4387531653 |
|---|---|
| doi | https://doi.org/10.54905/disssi.v17i39.e9dd1010 |
| ids.doi | https://doi.org/10.54905/disssi.v17i39.e9dd1010 |
| ids.openalex | https://openalex.org/W4387531653 |
| fwci | 0.0 |
| type | article |
| title | Effect of propranolol, bisoprolol and terbutaline in acute brain injury induced by malathion in the rat |
| biblio.issue | 39 |
| biblio.volume | 17 |
| biblio.last_page | 10 |
| biblio.first_page | 1 |
| topics[0].id | https://openalex.org/T11027 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.6711999773979187 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1308 |
| topics[0].subfield.display_name | Clinical Biochemistry |
| topics[0].display_name | Metabolism and Genetic Disorders |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780252434 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8445425033569336 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q424340 |
| concepts[0].display_name | Terbutaline |
| concepts[1].id | https://openalex.org/C2778151854 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8357358574867249 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q423364 |
| concepts[1].display_name | Propranolol |
| concepts[2].id | https://openalex.org/C2779670145 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6654855012893677 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q412515 |
| concepts[2].display_name | Bisoprolol |
| concepts[3].id | https://openalex.org/C2776638905 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6224998831748962 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q423005 |
| concepts[3].display_name | Malathion |
| concepts[4].id | https://openalex.org/C42219234 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5212615132331848 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q131130 |
| concepts[4].display_name | Anesthesia |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.4560437798500061 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C98274493 |
| concepts[6].level | 1 |
| concepts[6].score | 0.39015042781829834 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[6].display_name | Pharmacology |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3243844211101532 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C86803240 |
| concepts[8].level | 0 |
| concepts[8].score | 0.1389356255531311 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[8].display_name | Biology |
| concepts[9].id | https://openalex.org/C2776042228 |
| concepts[9].level | 2 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q35869 |
| concepts[9].display_name | Asthma |
| concepts[10].id | https://openalex.org/C6557445 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q173113 |
| concepts[10].display_name | Agronomy |
| concepts[11].id | https://openalex.org/C2778198053 |
| concepts[11].level | 2 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q181754 |
| concepts[11].display_name | Heart failure |
| concepts[12].id | https://openalex.org/C161176658 |
| concepts[12].level | 2 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q131656 |
| concepts[12].display_name | Pesticide |
| keywords[0].id | https://openalex.org/keywords/terbutaline |
| keywords[0].score | 0.8445425033569336 |
| keywords[0].display_name | Terbutaline |
| keywords[1].id | https://openalex.org/keywords/propranolol |
| keywords[1].score | 0.8357358574867249 |
| keywords[1].display_name | Propranolol |
| keywords[2].id | https://openalex.org/keywords/bisoprolol |
| keywords[2].score | 0.6654855012893677 |
| keywords[2].display_name | Bisoprolol |
| keywords[3].id | https://openalex.org/keywords/malathion |
| keywords[3].score | 0.6224998831748962 |
| keywords[3].display_name | Malathion |
| keywords[4].id | https://openalex.org/keywords/anesthesia |
| keywords[4].score | 0.5212615132331848 |
| keywords[4].display_name | Anesthesia |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.4560437798500061 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/pharmacology |
| keywords[6].score | 0.39015042781829834 |
| keywords[6].display_name | Pharmacology |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.3243844211101532 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/biology |
| keywords[8].score | 0.1389356255531311 |
| keywords[8].display_name | Biology |
| language | en |
| locations[0].id | doi:10.54905/disssi.v17i39.e9dd1010 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4387997631 |
| locations[0].source.issn | 2278-5396, 2278-540X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2278-5396 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Drug Discovery |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Drug Discovery |
| locations[0].landing_page_url | https://doi.org/10.54905/disssi.v17i39.e9dd1010 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5104181436 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Omar ME Abdel-Salam |
| authorships[0].countries | EG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Toxicology and Narcotics, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt |
| authorships[0].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[0].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[0].institutions[0].country_code | EG |
| authorships[0].institutions[0].display_name | National Research Centre |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Omar ME Abdel-Salam |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Toxicology and Narcotics, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt |
| authorships[1].author.id | https://openalex.org/A5013392061 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6109-5670 |
| authorships[1].author.display_name | Fatma A. Morsy |
| authorships[1].countries | EG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Pathology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt |
| authorships[1].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[1].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[1].institutions[0].country_code | EG |
| authorships[1].institutions[0].display_name | National Research Centre |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Fatma A Morsy |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Pathology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt |
| authorships[2].author.id | https://openalex.org/A5083649051 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3258-1810 |
| authorships[2].author.display_name | Amany A. Sleem |
| authorships[2].countries | EG |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt |
| authorships[2].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[2].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[2].institutions[0].country_code | EG |
| authorships[2].institutions[0].display_name | National Research Centre |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Amany A Sleem |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Effect of propranolol, bisoprolol and terbutaline in acute brain injury induced by malathion in the rat |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11027 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.6711999773979187 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1308 |
| primary_topic.subfield.display_name | Clinical Biochemistry |
| primary_topic.display_name | Metabolism and Genetic Disorders |
| related_works | https://openalex.org/W2087837045, https://openalex.org/W2074326769, https://openalex.org/W2024041551, https://openalex.org/W2385579688, https://openalex.org/W2256405346, https://openalex.org/W1995491897, https://openalex.org/W3186456742, https://openalex.org/W2021522630, https://openalex.org/W2369822981, https://openalex.org/W2387352974 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.54905/disssi.v17i39.e9dd1010 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4387997631 |
| best_oa_location.source.issn | 2278-5396, 2278-540X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2278-5396 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Drug Discovery |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Drug Discovery |
| best_oa_location.landing_page_url | https://doi.org/10.54905/disssi.v17i39.e9dd1010 |
| primary_location.id | doi:10.54905/disssi.v17i39.e9dd1010 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4387997631 |
| primary_location.source.issn | 2278-5396, 2278-540X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2278-5396 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Drug Discovery |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://discoveryjournals.org/drugdiscovery/current_issue/2023/v17/n39/e9dd1010.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Drug Discovery |
| primary_location.landing_page_url | https://doi.org/10.54905/disssi.v17i39.e9dd1010 |
| publication_date | 2023-06-15 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W2556677434, https://openalex.org/W2758802293, https://openalex.org/W2897301732, https://openalex.org/W2746993164, https://openalex.org/W2759742599, https://openalex.org/W2051221701, https://openalex.org/W2005319875, https://openalex.org/W2107952228, https://openalex.org/W2509891775, https://openalex.org/W2074454978, https://openalex.org/W2145643191, https://openalex.org/W2068997428, https://openalex.org/W2013542706, https://openalex.org/W2033260392, https://openalex.org/W1972752083, https://openalex.org/W2137809729, https://openalex.org/W2167716355, https://openalex.org/W2042791920, https://openalex.org/W2025540286, https://openalex.org/W2020477707, https://openalex.org/W2122386753, https://openalex.org/W2085534442, https://openalex.org/W2752136909, https://openalex.org/W1947666932, https://openalex.org/W2084734037, https://openalex.org/W2073401417, https://openalex.org/W1963711362, https://openalex.org/W2048191652, https://openalex.org/W1133236846, https://openalex.org/W2064699573, https://openalex.org/W4242232544, https://openalex.org/W1977942355, https://openalex.org/W1965156176, https://openalex.org/W2945065111, https://openalex.org/W2006370393, https://openalex.org/W2015351203 |
| referenced_works_count | 36 |
| abstract_inverted_index.1 | 108 |
| abstract_inverted_index.a | 274 |
| abstract_inverted_index.as | 49, 51, 149, 151 |
| abstract_inverted_index.at | 84, 104 |
| abstract_inverted_index.by | 76, 87, 114, 133, 191, 286 |
| abstract_inverted_index.in | 64, 129, 139, 156, 195, 240, 252, 266, 279 |
| abstract_inverted_index.no | 212 |
| abstract_inverted_index.of | 3, 11, 20, 38, 107, 118, 153, 158, 187, 200, 206, 220, 231, 242, 254, 268, 282 |
| abstract_inverted_index.on | 68, 215 |
| abstract_inverted_index.or | 63, 96, 101 |
| abstract_inverted_index.to | 34, 183, 197, 208, 235 |
| abstract_inverted_index.we | 32 |
| abstract_inverted_index.150 | 85 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.all | 103 |
| abstract_inverted_index.and | 16, 27, 55, 72, 126, 132, 146, 176, 193, 247 |
| abstract_inverted_index.but | 250 |
| abstract_inverted_index.for | 23, 91, 276 |
| abstract_inverted_index.had | 211 |
| abstract_inverted_index.may | 262 |
| abstract_inverted_index.not | 226, 251 |
| abstract_inverted_index.the | 9, 12, 18, 36, 39, 44, 52, 56, 105, 116, 119, 140, 162, 201, 237, 256, 264, 280, 283 |
| abstract_inverted_index.two | 92 |
| abstract_inverted_index.use | 10 |
| abstract_inverted_index.was | 112, 225, 233 |
| abstract_inverted_index.able | 234 |
| abstract_inverted_index.also | 272 |
| abstract_inverted_index.case | 253 |
| abstract_inverted_index.days | 93 |
| abstract_inverted_index.dose | 106 |
| abstract_inverted_index.drug | 54 |
| abstract_inverted_index.rats | 210, 243 |
| abstract_inverted_index.role | 275 |
| abstract_inverted_index.that | 260 |
| abstract_inverted_index.this | 30 |
| abstract_inverted_index.well | 50, 150 |
| abstract_inverted_index.were | 80, 179, 189 |
| abstract_inverted_index.with | 66, 82, 98, 245 |
| abstract_inverted_index.acute | 4, 77 |
| abstract_inverted_index.after | 181, 228 |
| abstract_inverted_index.aimed | 33 |
| abstract_inverted_index.alone | 62, 95 |
| abstract_inverted_index.brain | 69, 130, 134, 141, 157, 216, 222, 241, 267 |
| abstract_inverted_index.drugs | 22 |
| abstract_inverted_index.focal | 165 |
| abstract_inverted_index.lipid | 142 |
| abstract_inverted_index.mg/kg | 86 |
| abstract_inverted_index.other | 21 |
| abstract_inverted_index.oxide | 128, 148 |
| abstract_inverted_index.(i.p.) | 89 |
| abstract_inverted_index.caused | 75 |
| abstract_inverted_index.damage | 74, 111, 223, 285 |
| abstract_inverted_index.deeply | 167 |
| abstract_inverted_index.effect | 37 |
| abstract_inverted_index.either | 61, 94 |
| abstract_inverted_index.extent | 219 |
| abstract_inverted_index.levels | 117 |
| abstract_inverted_index.marked | 198 |
| abstract_inverted_index.marker | 144 |
| abstract_inverted_index.mg/kg, | 109 |
| abstract_inverted_index.nitric | 127, 147 |
| abstract_inverted_index.stress | 71, 121 |
| abstract_inverted_index.study, | 31 |
| abstract_inverted_index.tissue | 131 |
| abstract_inverted_index.agonist | 59 |
| abstract_inverted_index.besides | 8 |
| abstract_inverted_index.blocker | 42 |
| abstract_inverted_index.cardiac | 26 |
| abstract_inverted_index.changes | 186, 239 |
| abstract_inverted_index.cortex, | 164 |
| abstract_inverted_index.effects | 214 |
| abstract_inverted_index.entails | 7 |
| abstract_inverted_index.oximes, | 17 |
| abstract_inverted_index.present | 257 |
| abstract_inverted_index.rats.In | 161 |
| abstract_inverted_index.reduced | 124, 154, 227 |
| abstract_inverted_index.results | 258, 271 |
| abstract_inverted_index.suggest | 273 |
| abstract_inverted_index.treated | 81, 244 |
| abstract_inverted_index.addition | 196 |
| abstract_inverted_index.assessed | 113 |
| abstract_inverted_index.atropine | 15, 67, 192, 232 |
| abstract_inverted_index.cerebral | 163, 284 |
| abstract_inverted_index.combined | 97 |
| abstract_inverted_index.decrease | 263 |
| abstract_inverted_index.exposure | 182 |
| abstract_inverted_index.gliosis, | 170 |
| abstract_inverted_index.increase | 138 |
| abstract_inverted_index.indicate | 259 |
| abstract_inverted_index.neuronal | 73, 171 |
| abstract_inverted_index.observed | 180 |
| abstract_inverted_index.plaques, | 169 |
| abstract_inverted_index.rats.The | 270 |
| abstract_inverted_index.specific | 13 |
| abstract_inverted_index.antidotes | 14 |
| abstract_inverted_index.decreased | 190 |
| abstract_inverted_index.depletion | 152 |
| abstract_inverted_index.i.p.Brain | 110 |
| abstract_inverted_index.indicated | 136 |
| abstract_inverted_index.injection | 90 |
| abstract_inverted_index.malathion | 5, 78, 83, 159, 188, 246 |
| abstract_inverted_index.measuring | 115 |
| abstract_inverted_index.necrosis, | 173 |
| abstract_inverted_index.oxidative | 70, 120, 217 |
| abstract_inverted_index.poisoning | 6 |
| abstract_inverted_index.selective | 45, 57 |
| abstract_inverted_index.ameliorate | 236 |
| abstract_inverted_index.antagonist | 47 |
| abstract_inverted_index.apoptosis, | 172 |
| abstract_inverted_index.associated | 25 |
| abstract_inverted_index.biomarkers | 122 |
| abstract_inverted_index.bisoprolol | 48, 100 |
| abstract_inverted_index.homogenous | 166 |
| abstract_inverted_index.malathion. | 287 |
| abstract_inverted_index.management | 2 |
| abstract_inverted_index.spongiform | 177 |
| abstract_inverted_index.stress.The | 218 |
| abstract_inverted_index.antagonists | 249 |
| abstract_inverted_index.biochemical | 185 |
| abstract_inverted_index.combination | 65 |
| abstract_inverted_index.controlling | 24 |
| abstract_inverted_index.development | 281 |
| abstract_inverted_index.effects.The | 204 |
| abstract_inverted_index.glutathione | 125, 155 |
| abstract_inverted_index.investigate | 35 |
| abstract_inverted_index.problems.In | 29 |
| abstract_inverted_index.respiratory | 28 |
| abstract_inverted_index.significant | 137, 213 |
| abstract_inverted_index.stimulation | 278 |
| abstract_inverted_index.terbutaline | 207 |
| abstract_inverted_index.turbutaline | 102 |
| abstract_inverted_index.vacuolation | 175 |
| abstract_inverted_index.β-blockade | 261 |
| abstract_inverted_index.β-blockers | 194 |
| abstract_inverted_index.amelioration | 199 |
| abstract_inverted_index.degeneration | 178 |
| abstract_inverted_index.eosinophilic | 168 |
| abstract_inverted_index.histological | 221 |
| abstract_inverted_index.only-treated | 160 |
| abstract_inverted_index.perineuronal | 174 |
| abstract_inverted_index.peroxidation | 143 |
| abstract_inverted_index.propranolol, | 43, 99 |
| abstract_inverted_index.terbutaline, | 60 |
| abstract_inverted_index.βadrenergic | 248 |
| abstract_inverted_index.malathion.The | 184 |
| abstract_inverted_index.non-selective | 40 |
| abstract_inverted_index.administration | 19, 205, 230 |
| abstract_inverted_index.bronchodilator | 53 |
| abstract_inverted_index.intraperitoneal | 88 |
| abstract_inverted_index.malondialdehyde | 145 |
| abstract_inverted_index.pharmacological | 1 |
| abstract_inverted_index.terbutaline.The | 229 |
| abstract_inverted_index.β-adrenoceptor | 41, 277 |
| abstract_inverted_index.malondialdehyde, | 123 |
| abstract_inverted_index.β1-adrenoceptor | 46 |
| abstract_inverted_index.β2-adrenoceptor | 58 |
| abstract_inverted_index.histopthaological | 203 |
| abstract_inverted_index.malathion-induced | 202 |
| abstract_inverted_index.malathion-treated | 209, 269 |
| abstract_inverted_index.neurodegeneration | 265 |
| abstract_inverted_index.neuropathological | 238 |
| abstract_inverted_index.(neurodegeneration) | 224 |
| abstract_inverted_index.administration.Rats | 79 |
| abstract_inverted_index.histopathology.Results | 135 |
| abstract_inverted_index.terbutaline.Collectively, | 255 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.75 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.24393102 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |